Skip to main content

Table 1 Baseline characteristics of patients included in the study

From: Persistence and adverse events of biological treatment in adult patients with juvenile idiopathic arthritis: results from BIOBADASER

Variable

Median (IQR) (Years)

No. (%)

Total number of patients

 

469

Sex, female

 

216 (46.1)

Agea

32.8 [22.8–43.6]

 

Age at diagnosis

10.3 [4.4–14.3]

 

Age at the beginning of biological treatment, median [IQR]**

22.1 [13.9–32.5]

 

Years of disease progression

22.5 [12.3–33.9]

 

Time in treatment with biologic

9.7 [6.8–12.6]

 

JIA categories:

 - Oligoarticular, polyarticular, and systemic

331(70.5)

 - Enthesitis-related arthritis

117 (25)

 - Psoriatic arthritis

21 (4.5)

Positive RF

32 (6.8)

ANA-positive

111 (23.7)

HLA-B27-positive:

 - Positive

103 (22)

 - Negative

98 (20.9)

 - Not done

268 (57.1)

Uveitis:

 - Without uveitis

410 (87.4)

 - Uveitis, ANA-negative

30 (6.4)

 - Uveitis, ANA-positive

29 (6.2)

  1. Abbreviations: ANA Antinuclear antibodies, HLA Human leukocyte antigen, JIA Juvenile idiopathic arthritis, RF Rheumatoid factor
  2. aAge at the end of BIOBADASER phase II (December 2015)